Advancing Retinal Therapeutics Through Smarter Ocular Drug Delivery

Recent clinical milestones in retinal disease programs are accelerating interest in next-generation ocular drug delivery. Positive 36-month data from Lineage Cell Therapeutics’ RG6501 (OpRegen), alongside encouraging Phase 1/2a results for PER-001 from Perfuse Therapeutics, highlight a growing pipeline of innovative therapies that require durable, targeted delivery to the posterior segment of the eye.

As retinal therapeutics become more complex, delivery technologies must evolve to support sustained release, reduced injection frequency, and improved patient adherence - all while maintaining ocular safety and regulatory alignment.

These challenges will be addressed at the 4th Ophthalmic Drug Delivery Summit.

a leading forum dedicated to the design and development of advanced ocular drug delivery systems. The summit will cover key modalities including injectable depots and sustained-release implants, suprachoroidal injection technologies, biodegradable polymers and hydrogels, port delivery systems, and drug–device combination platforms.

Attendees will gain practical insights into which delivery strategies succeed in preclinical and clinical development, how companies are navigating regulatory and formulation trade-offs, and where innovation in retinal drug delivery is headed next.

Interest is already high, with teams from Boehringer Ingelheim, Character Biosciences, and HTL Biotechnologies confirmed to attend.

For professionals working in ophthalmology, retinal drug development, or ocular delivery systems, this summit offers a focused opportunity to stay ahead in a rapidly advancing field.